These findings establish three key conclusions: (1) BPA’s multi-target action underpins its obesogenic potency, (2) STAT3 and mTOR represent viable therapeutic targets, and (3) the lipid-atherosclerosis link reveals cardiovascular comorbidity risks—collectively necessitating enhanced regulation of BPA-containing products and accelerated development of molecular interventions. The gene discussed is STAT3; the disease is atherosclerosis.